Asia Pacific Nanomedicine Market Size & Outlook, 2023-2030
Asia Pacific nanomedicine market, 2018-2030 (US$M)
Related Markets
Asia Pacific nanomedicine market highlights
- The Asia Pacific nanomedicine market generated a revenue of USD 30,945.6 million in 2023.
- The market is expected to grow at a CAGR of 14.1% from 2024 to 2030.
- In terms of segment, drug delivery was the largest revenue generating application in 2023.
- Therapeutics is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 30,945.6 million |
| Market revenue in 2030 | USD 77,747.1 million |
| Growth rate | 14.1% (CAGR from 2023 to 2030) |
| Largest segment | Drug delivery |
| Fastest growing segment | Therapeutics |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Drug Delivery, Therapeutics, In-vitro Diagnostics, Implants, In-vivo Imaging |
| Key market players worldwide | Abbott Laboratories, Invitae Corp, Celgene, GE HealthCare Technologies Inc Common Stock, Johnson & Johnson, Mallinckrodt PLC Ordinary Shares - New, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Arrowhead Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 16.2% of the global nanomedicine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 77,747.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nanomedicine Market Scope
Nanomedicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific nanomedicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nanomedicine market will help companies and investors design strategic landscapes.
Drug delivery was the largest segment with a revenue share of 34.19% in 2023. Horizon Databook has segmented the Asia Pacific nanomedicine market based on drug delivery, therapeutics, in-vitro diagnostics, implants, in-vivo imaging covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific market of nanomedicine is expected to witness the fastest growth over the forecast period. The major factor contributing to this growth is emerging economies of Asian countries that allows patients to pay pharmaceutical costs out-of-pocket.
Presence of Nanyang Technological University (NTU) is established as Southeast Asia’s first nanomedicine research institute, which is engaged in implementation of nanotechnology for cardiovascular, skin therapeutics, diabetes, and ophthalmology.
Ongoing developments in nanoscience for groundbreaking advances in nanomedicine have offered immense opportunities for the progress of Asian nanomedicine market.
Reasons to subscribe to Asia Pacific nanomedicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific nanomedicine market databook
-
Our clientele includes a mix of nanomedicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific nanomedicine market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific nanomedicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific nanomedicine market size, by country, 2018-2030 (US$M)
Asia Pacific Nanomedicine Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
